The latest announcement is out from Epsilon Healthcare Limited ( (AU:EPN) ).
Epsilon Healthcare Limited has announced the renewal of its Medicinal Cannabis Permit for its subsidiary, Epsilon Pharma Pty Ltd, which allows for increased manufacturing quantities and grants both export and import licenses. This renewal signifies the company’s growing role in the medicinal cannabis industry and its commitment to expanding its manufacturing capabilities to meet rising demand, positioning Epsilon Healthcare as a key player in the healthcare landscape.
More about Epsilon Healthcare Limited
Epsilon Healthcare Limited is a prominent player in the pharmaceutical industry, specializing in contract development and manufacturing, telehealth, and pharmacy services. Its subsidiary, Epsilon Pharma Pty Ltd, operates a state-of-the-art facility in Southport, Queensland, and is recognized for its expertise in manufacturing a wide range of pharmaceutical products, including medicinal cannabis. The company is committed to innovation and diversification in the healthcare sector.
Technical Sentiment Signal: Buy
Current Market Cap: $4.66M
Find detailed analytics on EPN stock on TipRanks’ Stock Analysis page.